Top

Fibrogenesis & Tissue Repair

Published in:

Open Access 01-12-2015 | Research

In vitro reversion of activated primary human hepatic stellate cells

Authors: Adil El Taghdouini, Mustapha Najimi, Pau Sancho-Bru, Etienne Sokal, Leo A. van Grunsven

Published in: Fibrogenesis & Tissue Repair | Issue 1/2015

Abstract

Background

Liver fibrosis is characterized by the excessive formation and accumulation of matrix proteins as a result of wound healing in the liver. A main event during fibrogenesis is the activation of the liver resident quiescent hepatic stellate cell (qHSC). Recent studies suggest that reversion of the activated HSC (aHSC) phenotype into a quiescent-like phenotype could be a major cellular mechanism underlying fibrosis regression in the liver, thereby offering new therapeutic perspectives for the treatment of liver fibrosis. Whether human HSCs have the ability to undergo a similar reversion in phenotype is currently unknown. The aim of the present study is to identify experimental conditions that can revert the in vitro activated phenotype of primary human HSCs and consequently to map the molecular events associated with this reversion process by gene expression profiling.

Results

We find that epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF2) synergistically downregulate the expression of ACTA2 and LOX in primary human aHSCs. Their combination with oleic acid, palmitic acid, and retinol further potentiates a more quiescent-like phenotype as demonstrated by the abundant presence of retinyl ester-positive intra-cytoplasmic lipid droplets, low expression levels of activation markers, and a reduced basal as well as cytokine-stimulated proliferation and matrix metalloproteinase activity. Gene expression profiling experiments reveal that these in vitro reverted primary human HSCs (rHSCs) display an intermediary phenotype that is distinct from qHSCs and aHSCs. Interestingly, this intermediary phenotype is characterized by the increased expression of several previously identified signature genes of in vivo inactivated mouse HSCs such as CXCL1, CXCL2, and CTSS, suggesting also a potential role for these genes in promoting a quiescent-like phenotype in human HSCs.

Conclusions

We provide evidence for the ability of human primary aHSCs to revert in vitro to a transitional state through synergistic action of EGF, FGF2, dietary fatty acids and retinol, and provide a first phenotypic and genomic characterization of human in vitro rHSCs.

Available only for authorised users

Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209–18.PubMedCentralPubMedCrossRef

Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028–40.PubMedCentralPubMedCrossRef

Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823. doi:10.1038/ncomms3823.PubMedCentralPubMedCrossRef

Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88(1):125–72. doi:10.1152/physrev.00013.2007.PubMedCentralPubMedCrossRef

Reynaert H, Urbain D, Geerts A. Regulation of sinusoidal perfusion in portal hypertension. Anat Rec. 2008;291(6):693–8. doi:10.1002/ar.20669.CrossRef

Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology. 2008;135(5):1729–38. http://dx.doi.org/10.1053/j.gastro.2008.07.065.PubMedCrossRef

Geerts ABL, Wisse E. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis. 2001;21:311–35.PubMedCrossRef

Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol. 2012;56(5):1171–80. http://dx.doi.org/10.1016/j.jhep.2011.09.024.PubMedCrossRef

Iredale JPBRC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 1998;102:538–49.PubMedCentralPubMedCrossRef

10.

Issa R, Williams E, Trim N, Kendall T, Arthur MJP, Reichen J, et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut. 2001;48(4):548–57. doi:10.1136/gut.48.4.548.PubMedCentralPubMedCrossRef

11.

Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, Chatterjee K, et al. Peroxisome proliferator-activated receptor γ induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem. 2004;279(12):11392–401. doi:10.1074/jbc.M310284200.PubMedCrossRef

12.

She H, Xiong S, Hazra S, Tsukamoto H. Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem. 2005;280(6):4959–67. doi:10.1074/jbc.M410078200.PubMedCrossRef

13.

Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci. 2012;109(24):9448–53. doi:10.1073/pnas.1201840109.PubMedCentralPubMedCrossRef

14.

Troeger JS, Mederacke I, Gwak GY, Dapito DH, Mu X, Hsu CC, et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology. 2012;143(4):1073–83.e22. http://dx.doi.org/10.1053/j.gastro.2012.06.036.PubMedCrossRef

15.

Liu XXJ, Brenner DA, Kisseleva T. Reversibility of liver fibrosis and inactivation of fibrogenic myofibroblasts. Curr Pathobiol Rep. 2013;1(3):209–14.PubMedCentralPubMedCrossRef

16.

Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol. 2002;36(2):200–9. http://dx.doi.org/10.1016/S0168-8278(01)00260-4.PubMedCrossRef

17.

Niki T, Pekny M, Hellemans K, De Bleser P, Van Den Berg K, Vaeyens F, et al. Class VI intermediate filament protein nestin is induced during activation of rat hepatic stellate cells. Hepatology. 1999;29(2):520–7. doi:10.1002/hep.510290232.PubMedCrossRef

18.

Niki T, De Bleser PJ, Xu G, Van der Berg K, Wisse E, Geerts A. Comparison of glial fibrillary acidic protein and desmin staining in normal and CCl4-induced fibrotic rat livers. Hepatology. 1996;23(6):1538–45. doi:10.1002/hep.510230634.PubMedCrossRef

19.

D’Ambrosio DN, Walewski JL, Clugston RD, Berk PD, Rippe RA, Blaner WS. Distinct populations of hepatic stellate cells in the mouse liver have different capacities for retinoid and lipid storage. PLoS One. 2011;6(9), e24993. doi:10.1371/journal.pone.0024993.PubMedCentralPubMedCrossRef

20.

Hammel P, Couvelard A, O’Toole D, Ratouis A, Sauvanet A, Fléjou JF, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. New Engl J Med. 2001;344(6):418–23. doi:10.1056/NEJM200102083440604.PubMedCrossRef

21.

Kweon Y-O, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burkhardt E, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol. 2001;35(6):749–55. http://dx.doi.org/10.1016/S0168-8278(01)00218-5.PubMedCrossRef

22.

Arthur MJP. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology. 2002;122(5):1525–8. http://dx.doi.org/10.1053/gast.2002.33367.PubMedCrossRef

23.

Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39(6):1647–54. doi:10.1002/hep.20251.PubMedCrossRef

24.

Abdalla A, Zalata K, Ismail A, Shiha G, Attiya M, Abo-Alyazeed A. Regression of fibrosis in paediatric autoimmune hepatitis: morphometric assessment of fibrosis versus semiquantitative methods. Fibrogenesis Tissue Repair. 2009;2(1):2.PubMedCentralPubMedCrossRef

25.

Kömüves LG, Feren A, Jones AL, Fodor E. Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem. 2000;48(6):821–30. doi:10.1177/002215540004800610.PubMedCrossRef

26.

Olsen PS, Boesby S, Kirkegaard P, Therkelsen K, Almdal T, Poulsen SS, et al. Influence of epidermal growth factor on liver regeneration after partial hepatectomy in rats. Hepatology. 1988;8(5):992–6. doi:10.1002/hep.1840080503.CrossRef

27.

Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, et al. Prognostic gene expression signature for patients with hepatitis C–related early-stage cirrhosis. Gastroenterology. 2013;144(5):1024–30. http://dx.doi.org/10.1053/j.gastro.2013.01.021.PubMedCentralPubMedCrossRef

28.

Fuchs BC, Hoshida Y, Fujii T, Wei L, Yamada S, Lauwers GY, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology. 2014;59(4):1577–90. doi:10.1002/hep.26898.PubMedCentralPubMedCrossRef

29.

Rosenbaum J, Blazejewski S, Préaux A-M, Mallat A, Dhumeaux D, Mavier P. Fibroblast growth factor 2 and transforming growth factor β1 interactions in human liver myofibroblasts. Gastroenterology. 1995;109(6):1986–96. doi:10.1016/0016-5085(95)90767-x.PubMedCrossRef

30.

Ciccolini F, Svendsen CN. Fibroblast growth factor 2 (FGF-2) promotes acquisition of epidermal growth factor (EGF) responsiveness in mouse striatal precursor cells: identification of neural precursors responding to both EGF and FGF-2. J Neurosci. 1998;18(19):7869–80.PubMed

31.

Lee K-W, Thiyagarajan V, Sie H-W, Cheng M-F, Tsai M-J, Chia Y-C, et al. Synergistic effect of natural compounds on the fatty acid-induced autophagy of activated hepatic stellate cells. J Nutr Biochem. 2014;25(9):903–13. doi:10.1016/j.jnutbio.2014.04.001.PubMedCrossRef

32.

Mannaerts I, Schroyen B, Verhulst S, Van Lommel L, Schuit F, Nyssen M, et al. Gene expression profiling of early hepatic stellate cell activation reveals a role for Igfbp3 in cell migration. PLoS One. 2013;8(12), e84071. doi:10.1371/journal.pone.0084071.PubMedCentralPubMedCrossRef

33.

Mannaerts I, Leite SB, Verhulst S, Claerhout S, Eysackers N, Thoen LFR et al. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. Journal of Hepatology. Epub ahead of publication. doi:http://dx.doi.org/10.1016/j.jhep.2015.04.011.

34.

Miano JM, Long X, Fujiwara K. Serum response factor: master regulator of the actin cytoskeleton and contractile apparatus. 2007;292(1):C70-C81. doi:10.1152/ajpcell.00386.2006.

35.

Herrmann J, Haas U, Gressner AM, Weiskirchen R. TGF-β up-regulates serum response factor in activated hepatic stellate cells. Biochim Biophys Acta. 2007;1772(11–12):1250–7. http://dx.doi.org/10.1016/j.bbadis.2007.10.006.PubMedCrossRef

36.

Botella LM, Sanz-rodriguez F, Komi Y, Fernandez-l A, Varela E, Garrido-martin EM, et al. TGF-β regulates the expression of transcription factor KLF6 and its splice variants and promotes co-operative transactivation of common target genes through a Smad3–Sp1–KLF6 interaction. Biochem J. 2009;419(2):485–95. doi:10.1042/bj20081434.PubMedCentralPubMedCrossRef

37.

Kojima S, Hayashi S, Shimokado K, Suzuki Y, Shimada J, Crippa MP, et al. Transcriptional activation of urokinase by the Krüppel-like factor Zf9/COPEB activates latent TGF-β1 in vascular endothelial cells. Blood. 2000;95(4):1309–16.PubMed

38.

Zhang W, Ou J, Inagaki Y, Greenwel P, Ramirez F. Synergistic cooperation between Sp1 and Smad3/Smad4 mediates transforming growth factor β1 stimulation of α2(I)-collagen (COL1A2) transcription. J Biol Chem. 2000;275(50):39237–45. doi:10.1074/jbc.M003339200.PubMedCrossRef

39.

Lee M, Song SU, Ryu JK, Suh JK. Sp1-dependent regulation of the tissue inhibitor of metalloproteinases-1 promoter. J Cell Biochem. 2004;91(6):1260–8. doi:10.1002/jcb.20021.PubMedCrossRef

40.

Park J-H, Jo J-H, Kim K-H, Kim S-J, Lee W-R, Park K-K, et al. Antifibrotic effect through the regulation of transcription factor using ring type-Sp1 decoy oligodeoxynucleotide in carbon tetrachloride-induced liver fibrosis. J Gene Med. 2009;11(9):824–33. doi:10.1002/jgm.1355.PubMedCrossRef

41.

Chen H, Zhou Y, Chen KQ, An G, Ji SY, Chen QK. Anti-fibrotic effects via regulation of transcription factor Sp1 on hepatic stellate cells. Cell Physiol Biochem. 2012;29(1–2):51–60.PubMedCrossRef

42.

Tsukamoto H, She H, Hazra S, Cheng J, Miyahara T. Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. J Gastroenterol Hepatol. 2006;21:S102–5. doi:10.1111/j.1440-1746.2006.04573.x.PubMedCrossRef

43.

Madsen L, Petersen RK, Kristiansen K. Regulation of adipocyte differentiation and function by polyunsaturated fatty acids. Biochim Biophys Acta. 2005;1740(2):266–86. http://dx.doi.org/10.1016/j.bbadis.2005.03.001.PubMedCrossRef

44.

Galli A, Crabb D, Price D, Ceni E, Salzano R, Surrenti C, et al. Peroxisome proliferator-activated receptor γ transcriptional regulation is involved in platelet-derived growth factor–induced proliferation of human hepatic stellate cells. Hepatology. 2000;31(1):101–8. doi:10.1002/hep.510310117.PubMedCrossRef

45.

Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF, Motomura K, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem. 2000;275(46):35715–22. doi:10.1074/jbc.M006577200.PubMedCrossRef

46.

Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, et al. Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology. 2000;119(2):466–78. http://dx.doi.org/10.1053/gast.2000.9365.PubMedCrossRef

47.

Mikkelsen TS, Xu Z, Zhang X, Wang L, Gimble JM, Lander ES, et al. Comparative epigenomic analysis of murine and human adipogenesis. Cell. 2010;143(1):156–69. doi:10.1016/j.cell.2010.09.006.PubMedCentralPubMedCrossRef

48.

Wakabayashi K-i, Okamura M, Tsutsumi S, Nishikawa NS, Tanaka T, Sakakibara I, et al. The peroxisome proliferator-activated receptor γ/retinoid X receptor α heterodimer targets the histone modification enzyme PR-Set7/Setd8 gene and regulates adipogenesis through a positive feedback loop. Mol Cell Biol. 2009;29(13):3544–55. doi:10.1128/mcb.01856-08.PubMedCentralPubMedCrossRef

49.

Salma N, Xiao H, Mueller E, Imbalzano AN. Temporal recruitment of transcription factors and SWI/SNF chromatin-remodeling enzymes during adipogenic induction of the peroxisome proliferator-activated receptor γ nuclear hormone receptor. Mol Cell Biol. 2004;24(11):4651–63. doi:10.1128/mcb.24.11.4651-4663.2004.PubMedCentralPubMedCrossRef

50.

Siersbæk R, Nielsen R, John S, Sung M-H, Baek S, Loft A, et al. Extensive chromatin remodelling and establishment of transcription factor ‘hotspots’ during early adipogenesis. EMBO J. 2011;30(8):1459–72. doi:10.1038/emboj.2011.65.PubMedCentralPubMedCrossRef

51.

Eeckhoute J, Oger F, Staels B, Lefebvre P. Coordinated regulation of PPARγ expression and activity through control of chromatin structure in adipogenesis and obesity. PPAR Res. 2012;2012:9. doi:10.1155/2012/164140.CrossRef

52.

Imamura M, Inoguchi T, Ikuyama S, Taniguchi S, Kobayashi K, Nakashima N, et al. ADRP stimulates lipid accumulation and lipid droplet formation in murine fibroblasts. Am J Physiol Endocrinol Metab. 2002;283(4):E775–83. doi:10.1152/ajpendo.00040.2002.PubMedCrossRef

53.

Lee TF, Mak KM, Rackovsky O, Lin Y-L, Kwong AJ, Loke JC, et al. Downregulation of hepatic stellate cell activation by retinol and palmitate mediated by adipose differentiation-related protein (ADRP). J Cell Physiol. 2010;223(3):648–57. doi:10.1002/jcp.22063.PubMedCentralPubMed

54.

Guimarães ELM, Empsen C, Geerts A, van Grunsven LA. Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol. 2010;52(3):389–97. http://dx.doi.org/10.1016/j.jhep.2009.12.007.PubMedCrossRef

55.

Najimi M, Khuu DN, Lysy PA, Jazouli N, Abarca J, Sempoux C, et al. Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes? Cell Transplant. 2007;16(7):717–28.PubMedCrossRef

56.

Coll M, Taghdouini AE, Perea L, Mannaerts I, Vila-Casadesús M, Blaya D et al. Integrative miRNA and gene expression profiling analysis of human quiescent hepatic stellate cells. Sci Rep. 2015;5. doi:10.1038/srep11549.

57.

Mannaerts I, Nuytten NR, Rogiers V, Vanderkerken K, van Grunsven LA, Geerts A. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology. 2010;51(2):603–14. doi:10.1002/hep.23334.PubMedCrossRef

58.

Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31(4), e15. doi:10.1093/nar/gng015.PubMedCentralPubMedCrossRef

59.

Berardis S, Lombard C, Evraerts J, El Taghdouini A, Rosseels V, Sancho-Bru P, et al. Gene Expression Profiling and Secretome Analysis Differentiate Adult-Derived Human Liver Stem/Progenitor Cells and Human Hepatic Stellate Cells. PLoS ONE. 2014;9(1). doi:10.1371/journal.pone.0086137.

Title: In vitro reversion of activated primary human hepatic stellate cells
Authors: Adil El Taghdouini
Mustapha Najimi
Pau Sancho-Bru
Etienne Sokal
Leo A. van Grunsven
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Fibrogenesis & Tissue Repair / Issue 1/2015
Electronic ISSN: 1755-1536
DOI: https://doi.org/10.1186/s13069-015-0031-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Precision renal medicine: a roadmap towards targeted kidney fibrosis therapies

Workshop on cardiovascular extracellular matrix in health and disease in Baeza, Spain

Human lung myofibroblast TGFβ1-dependent Smad2/3 signalling is Ca2+-dependent and regulated by KCa3.1 K+ channels

Enhanced chemokine-receptor expression, function, and signaling in healthy African American and scleroderma-patient monocytes are regulated by caveolin-1

Donor caveolin 1 (CAV1) genetic polymorphism influences graft function after renal transplantation

Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials